



SUPPLEMENT APPROVAL

September 29, 2026

ADMA Biologics, Inc.
Attention: James Maloney
5800 Park of Commerce Boulevard, NW
Boca Raton, FL 33487

Dear Mr. Maloney:

We have approved your requests received March 30, 2026 to supplement your Biologics License Applications (BLAs) submitted under section 351(a) of the Public Health Service Act to lower the lot release specification for measles antibodies from “ $\geq 0.60 \times$ CBER reference standard lot 176, or $\geq 0.59 \times$ CBER reference standard lot 177” to ^{(b) (4)} $\times$ CBER reference standard lot 176 or lot 177,” in accordance with the FDA's November 5, 2018 notification letter to Immune Globulin (Human) Licensed Manufacturers for the following products:

STN Name of Biological Product

BL 125590/213	Immune Globulin Intravenous, Human-slra
BL 125389/367	Immune Globulin Intravenous (Human)

LABELING

We hereby approve the draft content of labeling Package Insert submitted under BL 125590/213, dated March 30, 2026.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, please submit the final content of labeling (21 CFR 601.14) in Structured Product Labeling (SPL) format via the FDA automated drug registration and listing system, (eLIST) as described at

<http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>.

Content of labeling must be identical to the Package Insert submitted on March 30, 2026. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As* at

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

All final labeling should be submitted as Product Correspondence to this BLA, STN BL 125590 and STN BL 125389 at the time of use and include implementation information on Form FDA 356h.

ADVERTISING AND PROMOTIONAL LABELING

You may submit two draft copies of the proposed introductory advertising and promotional labeling with Form FDA 2253 to the Advertising and Promotional Labeling Branch at the following address:

Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Ave.
WO71–G112
Silver Spring, MD 20993-0002

You must submit copies of your final advertising and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253 (21 CFR 601.12(f)(4)).

All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence or substantial clinical experience to support such claims (21 CFR 202.1(e)(6)).

For each pending supplemental application for this BLA that includes proposed revised labeling, please submit an amendment to update the proposed revised labeling with the changes approved today.

We will include information contained in the above-referenced supplements in your BLA files.

Sincerely,

Dorothy Scott, MD
Director
Division of Plasma Derivatives
Office of Plasma Protein Therapeutics
Office of Therapeutic Products
Center for Biologics Evaluation Research